



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	2.58
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	0.04  (1.575%)
Day Range	2.52 - 2.64
52-Week Range	2.20 - 5.02
Volume	1,705,711
Market Cap. (\$M)	322.784
Shares Out (M)	125.110

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jun 16, 2017*  
[Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team](#)
- Jun 16, 2017*  
[Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team](#)
- Jun 6, 2017*  
[Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference](#)
- Jun 6, 2017*  
[Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference](#)
- Jun 5, 2017*  
[Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

- Mar 14, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Definitive Proxy Statement](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*  
[Quarterly Report \(10-Q\)](#)